Suppr超能文献

用于氧化还原介导的抗癌治疗的细胞穿透肽共轭铜配合物

Cell-penetrating peptide-conjugated copper complexes for redox-mediated anticancer therapy.

作者信息

Peña Quim, Rodríguez-Calado Sergi, Simaan A Jalila, Capdevila Mercè, Bayón Pau, Palacios Oscar, Lorenzo Julia, Iranzo Olga

机构信息

Departament de Química, Facultat de Ciències, Universitat Autònoma de Barcelona, Barcelona, Spain.

Aix Marseille University, CNRS, Centrale Marseille, ISm2, Marseille, France.

出版信息

Front Pharmacol. 2022 Nov 15;13:1060827. doi: 10.3389/fphar.2022.1060827. eCollection 2022.

Abstract

Metal-based chemotherapeutics like cisplatin are widely employed in cancer treatment. In the last years, the design of redox-active (transition) metal complexes, such as of copper (Cu), has attracted high interest as alternatives to overcome platinum-induced side-effects. However, several challenges are still faced, including optimal aqueous solubility and efficient intracellular delivery, and strategies like the use of cell-penetrating peptides have been encouraging. In this context, we previously designed a Cu(II) scaffold that exhibited significant reactive oxygen species (ROS)-mediated cytotoxicity. Herein, we build upon the promising Cu(II) redox-active metallic core and aim to potentiate its anticancer activity by rationally tailoring it with solubility- and uptake-enhancing functionalizations that do not alter the ROS-generating Cu(II) center. To this end, sulfonate, arginine and arginine-rich cell-penetrating peptide (CPP) derivatives have been prepared and characterized, and all the resulting complexes preserved the parent Cu(II) coordination core, thereby maintaining its reported redox capabilities. Comparative assays in several cancer cell lines reveal that while specific solubility-targeting derivatizations (i.e., sulfonate or arginine) did not translate into an improved cytotoxicity, increased intracellular copper delivery CPP-conjugation promoted an enhanced anticancer activity, already detectable at short treatment times. Additionally, immunofluorescence assays show that the Cu(II) peptide-conjugate distributed throughout the cytosol without lysosomal colocalization, suggesting potential avoidance of endosomal entrapment. Overall, the systematic exploration of the tailored modifications enables us to provide further understanding on structure-activity relationships of redox-active metal-based (Cu(II)) cytotoxic complexes, which contributes to rationalize and improve the design of more efficient redox-mediated metal-based anticancer therapy.

摘要

像顺铂这样的金属基化疗药物在癌症治疗中被广泛应用。在过去几年中,氧化还原活性(过渡)金属配合物,如铜(Cu)配合物的设计,作为克服铂诱导副作用的替代方案引起了高度关注。然而,仍然面临一些挑战,包括最佳的水溶性和有效的细胞内递送,而使用细胞穿透肽等策略一直很有前景。在这种背景下,我们之前设计了一种Cu(II)支架,其表现出显著的活性氧(ROS)介导的细胞毒性。在此,我们基于有前景的Cu(II)氧化还原活性金属核心,旨在通过合理地用增强溶解性和摄取的功能化修饰来增强其抗癌活性,同时不改变产生ROS的Cu(II)中心。为此,制备并表征了磺酸盐、精氨酸和富含精氨酸的细胞穿透肽(CPP)衍生物,所有所得配合物都保留了母体Cu(II)配位核心,从而保持其已报道的氧化还原能力。在几种癌细胞系中的比较试验表明,虽然特定的靶向溶解性衍生化(即磺酸盐或精氨酸)并没有转化为改善的细胞毒性,但增加细胞内铜递送的CPP缀合促进了增强的抗癌活性,在短治疗时间内就已可检测到。此外,免疫荧光试验表明,Cu(II)肽缀合物分布在整个细胞质中,没有与溶酶体共定位,这表明可能避免了内体截留。总体而言,对定制修饰的系统探索使我们能够进一步理解氧化还原活性金属基(Cu(II))细胞毒性配合物的构效关系,这有助于合理化和改进更有效的氧化还原介导的金属基抗癌疗法的设计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2987/9714576/6dce4546db4f/FPHAR_fphar-2022-1060827_wc_abs.jpg

相似文献

1
Cell-penetrating peptide-conjugated copper complexes for redox-mediated anticancer therapy.
Front Pharmacol. 2022 Nov 15;13:1060827. doi: 10.3389/fphar.2022.1060827. eCollection 2022.
2
Copper(II) ,,-Chelating Complexes as Potential Anticancer Agents.
Inorg Chem. 2021 Mar 1;60(5):2939-2952. doi: 10.1021/acs.inorgchem.0c02932. Epub 2021 Feb 17.
3
Cu and Cu complexes with phosphine derivatives of fluoroquinolone antibiotics - A comparative study on the cytotoxic mode of action.
J Inorg Biochem. 2018 Apr;181:1-10. doi: 10.1016/j.jinorgbio.2018.01.008. Epub 2018 Jan 9.
6
CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Acta Biomater. 2016 Apr 15;35:280-92. doi: 10.1016/j.actbio.2016.02.005. Epub 2016 Feb 4.

引用本文的文献

1
's Copper-FomA Proteins: Driving Cancer Forward.
Inorg Chem. 2025 Aug 4;64(30):15502-15517. doi: 10.1021/acs.inorgchem.5c01747. Epub 2025 Jul 19.
2
In Vivo Interrogation of Cell-Penetrating Peptide Function: Accumulation in Tumors and the Potential as a Specific PET Probe.
Bioconjug Chem. 2025 May 21;36(5):1088-1097. doi: 10.1021/acs.bioconjchem.5c00128. Epub 2025 Apr 9.

本文引用的文献

1
The role of cell-penetrating peptides in potential anti-cancer therapy.
Clin Transl Med. 2022 May;12(5):e822. doi: 10.1002/ctm2.822.
2
Metallodrugs in cancer nanomedicine.
Chem Soc Rev. 2022 Apr 4;51(7):2544-2582. doi: 10.1039/d1cs00468a.
3
Metallodrugs are unique: opportunities and challenges of discovery and development.
Chem Sci. 2020 Nov 12;11(48):12888-12917. doi: 10.1039/d0sc04082g.
4
The evolution of commercial drug delivery technologies.
Nat Biomed Eng. 2021 Sep;5(9):951-967. doi: 10.1038/s41551-021-00698-w. Epub 2021 Apr 1.
5
The double-edged roles of ROS in cancer prevention and therapy.
Theranostics. 2021 Mar 4;11(10):4839-4857. doi: 10.7150/thno.56747. eCollection 2021.
6
Copper(II) ,,-Chelating Complexes as Potential Anticancer Agents.
Inorg Chem. 2021 Mar 1;60(5):2939-2952. doi: 10.1021/acs.inorgchem.0c02932. Epub 2021 Feb 17.
7
The rediscovery of platinum-based cancer therapy.
Nat Rev Cancer. 2021 Jan;21(1):37-50. doi: 10.1038/s41568-020-00308-y. Epub 2020 Oct 30.
8
Impact of the Endosomal Escape Activity of Cell-Penetrating Peptides on the Endocytic Pathway.
ACS Chem Biol. 2020 Sep 18;15(9):2355-2363. doi: 10.1021/acschembio.0c00319. Epub 2020 Aug 24.
9
Iron Promotes Dihydroartemisinin Cytotoxicity ROS Production and Blockade of Autophagic Flux Lysosomal Damage in Osteosarcoma.
Front Pharmacol. 2020 May 5;11:444. doi: 10.3389/fphar.2020.00444. eCollection 2020.
10
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.
Front Pharmacol. 2020 Mar 20;11:343. doi: 10.3389/fphar.2020.00343. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验